{"success":true,"data":{"pressRelease":{"id":"170848","rtpr_id":"nGNX9Mh0zx-20261015","ticker":"MDXH","exchange":"NASDAQ","all_tickers":["MDXH"],"title":"MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance","author":"Globe Newswire","published_at":"2026-10-15T20:00:00.501Z","article_body":"IRVINE, CA – October 15, 2026 (GlobeNewswire\n(https://www.globenewswire.com/Tracker?data=ol2IW7cCfpOsz-LLCZkJse8dCT5V8nAzy7UGlVbZB3qCJmx0lbfz54CuqnfygYOoewJzpdSBhcsF7ZmynDXL2v7KirOF7RpovGOnEIGfZ9OmEHVcsDic8fEDUjT7t2tSm01KcrS11aPs7fm-Y6Km9Q==))\n– MDxHealth SA (NASDAQ: MDXH) (the \"Company\" or \"mdxhealth\"), a leader in\nurology-focused precision diagnostics, today announced preliminary unaudited\nrevenue from continuing operations for the third quarter ended September 30,\n2026, and suspends its full-year 2026 revenue guidance of $110–115 million.\n\nThe Company expects to report third quarter 2026 revenue from continuing\noperations of approximately $22.7 million, compared to $22.7 million in the\nthird quarter of 2025 (re-presented to exclude Resolve mdx, which is reported\nas a discontinued operation). Third quarter tissue-based (Confirm mdx and GPS\nmdx) test volume was 11,232, a decrease of 11% from the prior-year period.\nThird quarter liquid-based (Exo mdx) test volume was 11,792 compared to 4,600\nin the prior-year period, which included Select mdx and Exo mdx from its\nSeptember 2025 acquisition. Cash and cash equivalents were approximately $31.7\nmillion as of September 30, 2026.\n\nMichael K. McGarrity, CEO of mdxhealth, commented: “Third quarter revenue\nfell short of our expectations. Following the discontinuation of Resolve mdx,\nwe experienced unexpected turnover within our sales force catalyzed by\naggressive targeting from recruiters. While we have a disciplined process\nwhich has served as the foundation of our forecast accuracy over the past\nthree years, that process was clearly disrupted by this recent impact on our\nsales force.\n\n“Although this led to an interruption in the progress we reported in Q2, we\nare focused on fortifying impacted territories and returning to consistent\nexecution. Importantly, we do not believe these factors represent a change in\nthe reputation that we have built with our customer base, the underlying\nclinical demand for our products, or our long-term market opportunity, and we\nexpect to return to growth within these end markets. We will provide\nadditional detail on our corrective actions and progress when we report our\nfull third quarter results and host our earnings call on November 12.”\n\nThe preliminary financial information in this press release is unaudited, is\nbased on management’s initial review of the Company’s results for the\nquarter ended September 30, 2026, and is subject to change upon completion of\nthe Company’s quarter-end financial close and review procedures. The\nCompany’s independent registered public accounting firm has not audited,\nreviewed or performed any procedures with respect to this preliminary\nfinancial information. Actual results may differ materially from these\npreliminary estimates.\n\nAbout mdxhealth\nMdxhealth is a leading precision diagnostics company that provides actionable\nmolecular information to personalize patient diagnosis and treatment. The\nCompany’s tests, based on proprietary genomic, epigenomic, exosomal and\nother molecular technologies, assist physicians with the diagnosis and\nprognosis of prostate cancer and other urologic diseases. For more\ninformation, visit mdxhealth.com and follow us on social media at:\ntwitter.com/mdxhealth, facebook.com/mdxhealth and\nlinkedin.com/company/mdxhealth.\n\nFor more information:\n\ninfo@mdxhealth.com\n\nLifeSci Advisors (IR & PR)\nJohn Fraunces\nManaging Director\nTel: +1 917 355 2395\n\nJfraunces@lifesciadvisors.com\n\nForward-Looking Statement: This press release contains forward-looking\nstatements and estimates with respect to the anticipated future performance of\nMDxHealth and the market in which it operates, all of which involve certain\nrisks and uncertainties. These statements are often, but are not always, made\nthrough the use of words or phrases such as “potential,” “expect,”\n“will,” “goal,” “next,” “potential,” “aim,” “explore,”\n“forward,” “future,” and “believes” as well as similar\nexpressions. Forward-looking statements contained in this release include, but\nare not limited to, statements regarding the Company’s preliminary unaudited\nfinancial results for the third quarter of 2026; expected future operating\nresults; our strategies, positioning, resources, capabilities, market\nopportunities and expectations for future events or performance; and the\nanticipated timing and benefits of our acquisitions, including estimated\nsynergies and other financial impacts. Such statements and estimates are based\non assumptions and assessments of known and unknown risks, uncertainties and\nother factors, which were deemed reasonable but may not prove to be correct.\nActual events are difficult to predict, may depend upon factors that are\nbeyond the company’s control, and may turn out to be materially different.\nExamples of forward-looking statements include, among others, statements we\nmake regarding expected future operating results, product development efforts,\nour strategies, positioning, resources, capabilities and expectations for\nfuture events or performance. Important factors that could cause actual\nresults, conditions and events to differ materially from those indicated in\nthe forward-looking statements include, among others, the following: our\nability to successfully and profitably market our products; our ability to\nrecruit, train and retain qualified sales personnel and the time required for\nnew sales personnel to reach full productivity; the risk that our final\nresults for the third quarter of 2026 differ from the preliminary results in\nthis release; the acceptance of our products and services by healthcare\nproviders; our ability to achieve and maintain adequate levels of coverage or\nreimbursement for our current and future solutions we commercialize or may\nseek to commercialize; the willingness of health insurance companies and other\npayers to cover our products and services and adequately reimburse us for such\nproducts and services; changes in payer claims reimbursement practices and\nMDxHealth estimates regarding collection amounts for tests; the results of\nrecoupment decisions and related appeals; the impacts and effectiveness of\nexiting from discontinued operations; our ability to obtain and maintain\nregulatory approvals and comply with applicable regulations; timing, progress\nand results of our research and development programs; the period over which we\nestimate our existing cash will be sufficient to fund our future operating\nexpenses and capital expenditure requirements; our ability to remain in\ncompliance with financial covenants made to and make scheduled payments to our\ncreditors; the possibility that the anticipated benefits from our business\nacquisitions like our acquisition of the ExoDx and GPS prostate cancer\nbusinesses will not be realized in full or at all or may take longer to\nrealize than expected; and the amount and nature of competition for our\nproducts and services. Other important risks and uncertainties are described\nin the Risk Factors sections of our most recent Annual Report on Form 20-F and\nin our other reports filed with the Securities and Exchange Commission.\nMDxHealth expressly disclaims any obligation to update any such\nforward-looking statements in this release to reflect any change in its\nexpectations with regard thereto or any change in events, conditions or\ncircumstances on which any such statement is based unless required by law or\nregulation. This press release does not constitute an offer or invitation for\nthe sale or purchase of securities or assets of MDxHealth in any jurisdiction.\nNo securities of MDxHealth may be offered or sold within the United States\nwithout registration under the U.S. Securities Act of 1933, as amended, or in\ncompliance with an exemption therefrom, and in accordance with any applicable\nU.S. securities laws.\n\nNOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Genomic Prostate\nScore, GPS mdx, Exosome Diagnostics, ExosomeDx, Exo mdx, ExoDx, ExoDx Prostate\nIntelliscore (EPI), and Monitor mdx are trademarks or registered trademarks of\nMDxHealth SA and its affiliates. The GPS test was formerly known as and is\nfrequently referenced in guidelines, coverage policies, reimbursement\ndecisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype\nDX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer\nAssay, among others. The Oncotype DX trademark and all other trademarks and\nservice marks, are the property of their respective owners.\n\nAttachment\n*     MDXH Q326 pre-release FINAL\n(https://ml-eu.globenewswire.com/Resource/Download/13861aa5-6ffe-4e7a-ba57-955871df9d19)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/695db10e-2b5a-44e3-af73-a3dea1ead37c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9Mh0zx-20261015","title":"MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance","author":"Globe Newswire","ticker":"MDXH","created":"2026-10-15T20:00:00.501Z","tickers":["MDXH"],"exchange":"NASDAQ","article_body":"IRVINE, CA – October 15, 2026 (GlobeNewswire\n(https://www.globenewswire.com/Tracker?data=ol2IW7cCfpOsz-LLCZkJse8dCT5V8nAzy7UGlVbZB3qCJmx0lbfz54CuqnfygYOoewJzpdSBhcsF7ZmynDXL2v7KirOF7RpovGOnEIGfZ9OmEHVcsDic8fEDUjT7t2tSm01KcrS11aPs7fm-Y6Km9Q==))\n– MDxHealth SA (NASDAQ: MDXH) (the \"Company\" or \"mdxhealth\"), a leader in\nurology-focused precision diagnostics, today announced preliminary unaudited\nrevenue from continuing operations for the third quarter ended September 30,\n2026, and suspends its full-year 2026 revenue guidance of $110–115 million.\n\nThe Company expects to report third quarter 2026 revenue from continuing\noperations of approximately $22.7 million, compared to $22.7 million in the\nthird quarter of 2025 (re-presented to exclude Resolve mdx, which is reported\nas a discontinued operation). Third quarter tissue-based (Confirm mdx and GPS\nmdx) test volume was 11,232, a decrease of 11% from the prior-year period.\nThird quarter liquid-based (Exo mdx) test volume was 11,792 compared to 4,600\nin the prior-year period, which included Select mdx and Exo mdx from its\nSeptember 2025 acquisition. Cash and cash equivalents were approximately $31.7\nmillion as of September 30, 2026.\n\nMichael K. McGarrity, CEO of mdxhealth, commented: “Third quarter revenue\nfell short of our expectations. Following the discontinuation of Resolve mdx,\nwe experienced unexpected turnover within our sales force catalyzed by\naggressive targeting from recruiters. While we have a disciplined process\nwhich has served as the foundation of our forecast accuracy over the past\nthree years, that process was clearly disrupted by this recent impact on our\nsales force.\n\n“Although this led to an interruption in the progress we reported in Q2, we\nare focused on fortifying impacted territories and returning to consistent\nexecution. Importantly, we do not believe these factors represent a change in\nthe reputation that we have built with our customer base, the underlying\nclinical demand for our products, or our long-term market opportunity, and we\nexpect to return to growth within these end markets. We will provide\nadditional detail on our corrective actions and progress when we report our\nfull third quarter results and host our earnings call on November 12.”\n\nThe preliminary financial information in this press release is unaudited, is\nbased on management’s initial review of the Company’s results for the\nquarter ended September 30, 2026, and is subject to change upon completion of\nthe Company’s quarter-end financial close and review procedures. The\nCompany’s independent registered public accounting firm has not audited,\nreviewed or performed any procedures with respect to this preliminary\nfinancial information. Actual results may differ materially from these\npreliminary estimates.\n\nAbout mdxhealth\nMdxhealth is a leading precision diagnostics company that provides actionable\nmolecular information to personalize patient diagnosis and treatment. The\nCompany’s tests, based on proprietary genomic, epigenomic, exosomal and\nother molecular technologies, assist physicians with the diagnosis and\nprognosis of prostate cancer and other urologic diseases. For more\ninformation, visit mdxhealth.com and follow us on social media at:\ntwitter.com/mdxhealth, facebook.com/mdxhealth and\nlinkedin.com/company/mdxhealth.\n\nFor more information:\n\ninfo@mdxhealth.com\n\nLifeSci Advisors (IR & PR)\nJohn Fraunces\nManaging Director\nTel: +1 917 355 2395\n\nJfraunces@lifesciadvisors.com\n\nForward-Looking Statement: This press release contains forward-looking\nstatements and estimates with respect to the anticipated future performance of\nMDxHealth and the market in which it operates, all of which involve certain\nrisks and uncertainties. These statements are often, but are not always, made\nthrough the use of words or phrases such as “potential,” “expect,”\n“will,” “goal,” “next,” “potential,” “aim,” “explore,”\n“forward,” “future,” and “believes” as well as similar\nexpressions. Forward-looking statements contained in this release include, but\nare not limited to, statements regarding the Company’s preliminary unaudited\nfinancial results for the third quarter of 2026; expected future operating\nresults; our strategies, positioning, resources, capabilities, market\nopportunities and expectations for future events or performance; and the\nanticipated timing and benefits of our acquisitions, including estimated\nsynergies and other financial impacts. Such statements and estimates are based\non assumptions and assessments of known and unknown risks, uncertainties and\nother factors, which were deemed reasonable but may not prove to be correct.\nActual events are difficult to predict, may depend upon factors that are\nbeyond the company’s control, and may turn out to be materially different.\nExamples of forward-looking statements include, among others, statements we\nmake regarding expected future operating results, product development efforts,\nour strategies, positioning, resources, capabilities and expectations for\nfuture events or performance. Important factors that could cause actual\nresults, conditions and events to differ materially from those indicated in\nthe forward-looking statements include, among others, the following: our\nability to successfully and profitably market our products; our ability to\nrecruit, train and retain qualified sales personnel and the time required for\nnew sales personnel to reach full productivity; the risk that our final\nresults for the third quarter of 2026 differ from the preliminary results in\nthis release; the acceptance of our products and services by healthcare\nproviders; our ability to achieve and maintain adequate levels of coverage or\nreimbursement for our current and future solutions we commercialize or may\nseek to commercialize; the willingness of health insurance companies and other\npayers to cover our products and services and adequately reimburse us for such\nproducts and services; changes in payer claims reimbursement practices and\nMDxHealth estimates regarding collection amounts for tests; the results of\nrecoupment decisions and related appeals; the impacts and effectiveness of\nexiting from discontinued operations; our ability to obtain and maintain\nregulatory approvals and comply with applicable regulations; timing, progress\nand results of our research and development programs; the period over which we\nestimate our existing cash will be sufficient to fund our future operating\nexpenses and capital expenditure requirements; our ability to remain in\ncompliance with financial covenants made to and make scheduled payments to our\ncreditors; the possibility that the anticipated benefits from our business\nacquisitions like our acquisition of the ExoDx and GPS prostate cancer\nbusinesses will not be realized in full or at all or may take longer to\nrealize than expected; and the amount and nature of competition for our\nproducts and services. Other important risks and uncertainties are described\nin the Risk Factors sections of our most recent Annual Report on Form 20-F and\nin our other reports filed with the Securities and Exchange Commission.\nMDxHealth expressly disclaims any obligation to update any such\nforward-looking statements in this release to reflect any change in its\nexpectations with regard thereto or any change in events, conditions or\ncircumstances on which any such statement is based unless required by law or\nregulation. This press release does not constitute an offer or invitation for\nthe sale or purchase of securities or assets of MDxHealth in any jurisdiction.\nNo securities of MDxHealth may be offered or sold within the United States\nwithout registration under the U.S. Securities Act of 1933, as amended, or in\ncompliance with an exemption therefrom, and in accordance with any applicable\nU.S. securities laws.\n\nNOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Genomic Prostate\nScore, GPS mdx, Exosome Diagnostics, ExosomeDx, Exo mdx, ExoDx, ExoDx Prostate\nIntelliscore (EPI), and Monitor mdx are trademarks or registered trademarks of\nMDxHealth SA and its affiliates. The GPS test was formerly known as and is\nfrequently referenced in guidelines, coverage policies, reimbursement\ndecisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype\nDX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer\nAssay, among others. The Oncotype DX trademark and all other trademarks and\nservice marks, are the property of their respective owners.\n\nAttachment\n*     MDXH Q326 pre-release FINAL\n(https://ml-eu.globenewswire.com/Resource/Download/13861aa5-6ffe-4e7a-ba57-955871df9d19)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/695db10e-2b5a-44e3-af73-a3dea1ead37c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-15T20:00:00.548070119Z","server_sent_at_ms":1792094400548},"received_at":"2026-10-15T20:00:00.683Z","source_url":null},"analysis":{"id":"159025","press_release_id":"170848","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["full-year revenue guidance suspended","11% decline in tissue-based test volume","sales-force turnover disrupting execution","limited cash position of ~$31.7 million"],"eventType":"guidance_update","narrative":"MDxHealth announced preliminary unaudited Q3 2026 revenue of approximately $22.7 million, flat versus the prior year, and said revenue fell short of expectations.\n\nThe company suspended its full-year 2026 revenue guidance of $110-115 million, citing unexpected sales-force turnover following the discontinuation of Resolve mdx.\n\nTissue-based test volume fell 11% to 11,232, while liquid-based (Exo mdx) volume grew to 11,792 from 4,600. Cash stood at roughly $31.7 million; full results and an earnings call are set for November 12.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Guidance suspension on flat preliminary revenue amid sales-force attrition -- watch November 12 call for corrective actions."},"keyFigures":{"revenue":22700000,"guidance":"Full-year 2026 revenue guidance of $110-115 million suspended","revenueYoy":"0%","customDimensions":{"liquid_test_volume":11792,"tissue_test_volume":11232,"cash_and_equivalents":31700000,"tissue_test_volume_yoy":"-11%","liquid_test_volume_prior_year":4600}},"quotedText":"Third quarter revenue fell short of our expectations. Following the discontinuation of Resolve mdx, we experienced unexpected turnover within our sales force catalyzed by aggressive targeting from recruiters.","namedEntities":{"people":[{"name":"Michael K. McGarrity","role":"CEO"},{"name":"John Fraunces","role":"Managing Director, LifeSci Advisors (IR & PR)"}],"products":["Confirm mdx","GPS mdx","Exo mdx","Select mdx","Resolve mdx"],"companies":[{"name":"MDxHealth SA","ticker":"MDXH"},{"name":"LifeSci Advisors","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$22.7 million","context":"preliminary Q3 2026 revenue from continuing operations"},{"amount":"$110–115 million","context":"suspended full-year 2026 revenue guidance"},{"amount":"$31.7 million","context":"cash and cash equivalents as of September 30, 2026"}]},"materialImpact":{"score":3,"reasoning":"Preliminary Q3 revenue was flat YoY at ~$22.7M and fell short of expectations, and the company suspended its full-year 2026 revenue guidance of $110-115M. Tissue-based test volumes fell 11%, with sales-force turnover cited as the cause."},"tickerRelevance":{"others":[],"primary":"MDXH"},"globalImportance":30,"audienceRelevance":25,"eventTypeSecondary":["earnings"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"guidance suspension with preliminary revenue miss","sectorWeight":"moderate (diagnostics)","issuerAuthored":true}},"event_type":"guidance_update","event_type_secondary":["earnings"],"sentiment":"bearish","material_impact_score":3,"narrative":"MDxHealth announced preliminary unaudited Q3 2026 revenue of approximately $22.7 million, flat versus the prior year, and said revenue fell short of expectations.\n\nThe company suspended its full-year 2026 revenue guidance of $110-115 million, citing unexpected sales-force turnover following the discontinuation of Resolve mdx.\n\nTissue-based test volume fell 11% to 11,232, while liquid-based (Exo mdx) volume grew to 11,792 from 4,600. Cash stood at roughly $31.7 million; full results and an earnings call are set for November 12.","key_figures":{"revenue":22700000,"guidance":"Full-year 2026 revenue guidance of $110-115 million suspended","revenueYoy":"0%","customDimensions":{"liquid_test_volume":11792,"tissue_test_volume":11232,"cash_and_equivalents":31700000,"tissue_test_volume_yoy":"-11%","liquid_test_volume_prior_year":4600}},"named_entities":{"people":[{"name":"Michael K. McGarrity","role":"CEO"},{"name":"John Fraunces","role":"Managing Director, LifeSci Advisors (IR & PR)"}],"products":["Confirm mdx","GPS mdx","Exo mdx","Select mdx","Resolve mdx"],"companies":[{"name":"MDxHealth SA","ticker":"MDXH"},{"name":"LifeSci Advisors","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$22.7 million","context":"preliminary Q3 2026 revenue from continuing operations"},{"amount":"$110–115 million","context":"suspended full-year 2026 revenue guidance"},{"amount":"$31.7 million","context":"cash and cash equivalents as of September 30, 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T20:00:05.406Z","global_importance":30,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"guidance suspension with preliminary revenue miss","sectorWeight":"moderate (diagnostics)","issuerAuthored":true}},"durationMs":4656,"modelName":"glm-5.3-flashx"}}